METABIOMED.CO.,LTD: debt-to-equity, ROE and more
KOSDAQ, Legal name METABIOMED.CO.,LTD
Latest figures are the FY2025 consolidated summary statements.
Latest fiscal year ratios (computed here)
- Debt/equity
- 49.4%
- Equity ratio
- 66.9%
- ROE
- 8.6%
- Op. margin
- 20.8%
- Rev. growth
- 9.5%
- Interest coverage
- n/a
Condition flags
- Operating profit for 5 straight years.
- Total equity is above paid-in capital. Not capital-impaired.
Interest coverage and dividends (OpenDART)
Interest expense and dividends come from DART's OpenDART annual-report filings, not the FSC summary statements used above. The source differs from the other tables on this page.
Interest coverage = operating profit ÷ interest expenseNo interest expense value yet for this company. Most companies fold interest expense into a single finance-costs line on their income statement, so it cannot be pulled out separately. Interest coverage is not computed here.
Dividends, last 3 fiscal years
| Fiscal year | Cash dividend per share | Payout ratio |
|---|---|---|
| 2025 | ₩105 | 25.9% |
| 2024 | ₩30 | 3.1% |
| 2023 | ₩20 | 4.5% |
Cash dividends for 3 straight years (only the 3 years OpenDART returns).
Source values from the OpenDART (금융감독원 전자공시) annual report. Report fiscal year 2025.
Ratios by year (computed here)
Debt-to-equity = total liabilities ÷ total equity × 100Equity ratio = total equity ÷ total assets × 100ROE = net income ÷ year-end total equity × 100Operating margin = operating profit ÷ revenue × 100Revenue growth = (this year − last year) ÷ last year × 100
Computed from the source figures above with these formulas. Where the source's own debt-to-equity differs from ours, both are shown for that year.
| Fiscal year | Debt/equity | Equity ratio | ROE | Op. margin | Rev. growth |
|---|---|---|---|---|---|
| FY2021 consolidated | 71.6% | 58.3% | 16.1% | 8.4% | n/a |
| FY2022 consolidated | 90.8% | 52.4% | 5.7% | 7.7% | 17.3% |
| FY2023 consolidated | 79.1% | 55.8% | 13.5% | 12.9% | 20.5% |
| FY2024 consolidated | 84.5% | 54.2% | 23.2% | 18.3% | 13.2% |
| FY2025 consolidated | 49.4% | 66.9% | 8.6% | 20.8% | 9.5% |
Source figures (FSC summary statements)
Amounts are the source values, shortened. A cell reported as zero may be blank in the source, so it is not used in any ratio.
| Fiscal year | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | ₩58.8B | ₩68.9B | ₩83.1B | ₩94.0B | ₩103.0B |
| Operating profit | ₩4.9B | ₩5.3B | ₩10.7B | ₩17.2B | ₩21.4B |
| Pre-tax income | ₩7.6B | ₩4.0B | ₩7.8B | ₩23.3B | ₩12.6B |
| Net income | ₩9.7B | ₩3.6B | ₩9.8B | ₩22.3B | ₩10.8B |
| Total assets | ₩103.1B | ₩121.1B | ₩130.1B | ₩177.3B | ₩186.6B |
| Total liabilities | ₩43.0B | ₩57.6B | ₩57.5B | ₩81.2B | ₩61.7B |
| Total equity | ₩60.1B | ₩63.4B | ₩72.7B | ₩96.1B | ₩124.9B |
| Paid-in capital | ₩11.9B | ₩11.9B | ₩11.9B | ₩11.9B | ₩14.0B |
| Debt/equity (source value) | 71.6% | 90.8% | 79.1% | 84.5% | 49.4% |
Company outline (FSC)
- Market
- KOSDAQ
- Fiscal year end
- Dec
- Founded
- 1999-07-01
- Listed
- 08/04/15
- Employees
- 345
- Auditor
- 삼덕회계법인
- Audit opinion
- 적정의견
- Corporate reg. no.
- 1501110041925
- Outline updated
- 2026-09-24
Check the original filings
Read the annual report and audit report before you decide anything. The link opens a DART search for this company's name.
Search DART for 메타바이오메드Computed from the Financial Services Commission's company outline and summary statements (data.go.kr). Data as of 2026-09-24.